STOCKS CLIMB AS RATE-HIKE FEARS FADE, WITH APPLE ON DECK

Wall Street bracing for drop in revenue, potentially hefty pullback in iPhone sales in China

Alnylam Pharmaceuticals, Inc. (DUL.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR

Add to watchlist

138.80

+2.15

(+1.57%)

As of 08:20AM CEST. Market open.

Loading interactive chart...

Zacks
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
Alnylam (ALNY) delivered earnings and revenue surprises of 78.67% and 17.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business Wire
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
CAMBRIDGE, Mass., May 02, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2024 and reviewed recent business highlights.
Zacks
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.